65.22
Cidara Therapeutics Inc Aktie (CDTX) Neueste Nachrichten
Cidara Therapeutics: A High-Conviction Biotech Play with Clear Path to FDA Phase 3 and Market Disruption - AInvest
Cidara Therapeutics: Still Big Catalysts Ahead Following Impressive Ph2b Readout (CDTX) - Seeking Alpha
Cidara Therapeutics: Promising Trials Amidst Financial Challenges - MSN
Fund Update: MORGAN STANLEY added 875,198 shares of CIDARA THERAPEUTICS (CDTX) to their portfolio - Quiver Quantitative
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Q2 2025 Earnings Call Transcript - MSN
Cidara (CDTX) Q2 Cash Surges 163% - AOL.com
Cidara Therapeutics Inc. Pullback Analyzed — Is It Time to ExitMarket Entry and Exit Point Tips From Traders - beatles.ru
A Quick Look at Today's Ratings for Cidara Therapeutics(CDTX.US), With a Forecast Between $66 to $74 - 富途牛牛
Cidara Therapeutics 2024 Q2 Earnings Net Loss Widens by 569.5% - AInvest
Cidara Therapeutics price target raised to $74 from $54 at Needham - TipRanks
Guggenheim raises Cidara Therapeutics stock price target to $70 on FDA meeting progress - Investing.com Canada
Cidara Therapeutics Rallies On Promising Flu Drug Progress - Finimize
Cidara Therapeutics Reports Positive Trial Results and Financial Growth - TipRanks
Earnings call transcript: Sidera Therapeutics’ Q2 2025 innovation focus - Investing.com
Cidara Therapeutics: Q2 Earnings Snapshot - Manistee News Advocate
Cidara Therapeutics stock price target raised to $66 at Citizens JMP - Investing.com Australia
Cidara Therapeutics Inc (CDTX) Q2 2025 Earnings Call Highlights: Promising Clinical Trial ... - Yahoo Finance
Cidara Therapeutics Inc (CDTX) Q2 2025 Earnings Call Highlights: Promising Clinical Trial ... By GuruFocus - Investing.com Canada
Cidara Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cidara Therapeutics 2024 Q2 Earnings Deepened Losses Amid Strong Clinical Progress - AInvest
Transcript : Cidara Therapeutics, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Cidara Therapeutics reports Q2 EPS ($1.65), consensus ($1.82) - TipRanks
Cidara Therapeutics Q2 net loss narrows - MarketScreener
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results - GlobeNewswire
Spero leads infectious disease gains with 252% stock jump - BioWorld MedTech
RBC Capital raises Cidara Therapeutics stock price target to $115 on market potential - Investing.com Canada
Cidara Therapeutics price target raised to $115 from $75 at RBC Capital - TipRanks
Cidara Therapeutics Inc expected to post a loss of $2.00 a shareEarnings Preview - TradingView
Cidara Therapeutics CDTX Q2 2025 Earnings Preview Upside Potential on Analyst Optimism - AInvest
Is Cidara Therapeutics Inc. stock overvalued or undervaluedCapitalize on market momentum for maximum gains - Jammu Links News
Should I hold or sell Cidara Therapeutics Inc. stock in 2025Achieve breakthrough gains with expert advice - Jammu Links News
Cidara Therapeutics Inc. Stock Analysis and ForecastInvest smarter with data-backed insights - Jammu Links News
How strong is Cidara Therapeutics Inc. company’s balance sheetGet daily updates on promising stocks - Jammu Links News
What institutional investors are buying Cidara Therapeutics Inc. stockBuild a diversified portfolio for risk management - Jammu Links News
What makes Cidara Therapeutics Inc. stock price move sharplyRecord-breaking capital gains - Jammu Links News
Is Cidara Therapeutics Inc. a good long term investmentInvest with confidence backed by data - Jammu Links News
What are analysts’ price targets for Cidara Therapeutics Inc. in the next 12 monthsDynamic portfolio growth - Jammu Links News
What is the risk reward ratio of investing in Cidara Therapeutics Inc. stockAchieve rapid wealth accumulation through smart investing - Jammu Links News
What is the dividend policy of Cidara Therapeutics Inc. stockFree Trading Psychology Coaching - Jammu Links News
What are Cidara Therapeutics Inc. company’s key revenue driversAchieve rapid capital gains with smart investing - Jammu Links News
Will Cidara Therapeutics Inc. Bounce From 52 Week LowTriple Digit Growth Focused Trade Plan Reviewed - metal.it
Moving Average Crossover Confirms Uptrend in Cidara Therapeutics Inc.Real Time Alerts Based on AI Prediction Triggered - metal.it
How Cidara Therapeutics Inc. stock performs during market volatilityHigh Win Rate Trading Opportunities Detected - beatles.ru
Can trapped investors hope for a rebound in Cidara Therapeutics Inc.Real-Time Trade Insights Spark Market Reactions - metal.it
Will Cidara Therapeutics Inc. stock split in the near futureInvestment Strategy With Predictable Gains Outlined - metal.it
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):